SRR1375976
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.450
- PANCREAS_BETA_CELLS+0.386
- SPERMATOGENESIS+0.221
- MYOGENESIS+0.201
- UV_RESPONSE_DN+0.198
- HEDGEHOG_SIGNALING+0.175
- APICAL_SURFACE+0.165
- ESTROGEN_RESPONSE_LATE+0.155
- BILE_ACID_METABOLISM+0.126
- ESTROGEN_RESPONSE_EARLY+0.122
Top 10 suppressed
- MYC_TARGETS_V1-0.564
- UNFOLDED_PROTEIN_RESPONSE-0.481
- INTERFERON_ALPHA_RESPONSE-0.479
- DNA_REPAIR-0.466
- E2F_TARGETS-0.453
- MYC_TARGETS_V2-0.448
- G2M_CHECKPOINT-0.437
- PROTEIN_SECRETION-0.414
- IL6_JAK_STAT3_SIGNALING-0.403
- INTERFERON_GAMMA_RESPONSE-0.375
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1418127 | GTEX | — | 0.972 |
| 2 | SRR1444678 | GTEX | — | 0.959 |
| 3 | SRR1405007 | GTEX | — | 0.957 |
| 4 | SRR1314958 | GTEX | — | 0.957 |
| 5 | SRR1341763 | GTEX | — | 0.954 |
| 6 | SRR1435484 | GTEX | — | 0.953 |
| 7 | SRR1407134 | GTEX | — | 0.950 |
| 8 | BS_C7N3J4NW | high-grade glioma | — | 0.949 |
| 9 | SRR1477080 | GTEX | — | 0.949 |
| 10 | SRR614900 | GTEX | — | 0.949 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 13 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.450 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.386 | Cobimetinib | — uncovered |
| SPERMATOGENESIS | 0.221 | Inavolisib | — uncovered |
| MYOGENESIS | 0.201 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.198 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.175 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.165 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.155 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.126 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.122 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.075 | Remibrutinib | — uncovered |
| COAGULATION | 0.062 | Binimetinib | — uncovered |
| KRAS_SIGNALING_UP | 0.039 | Inavolisib | — uncovered |